Senti Biosciences Holdings, Inc. (SNTI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. The company is currently focused on advancing its lead product candidate, SENTI-202, for hematologic malignancies. As of the reporting date, the company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Loss | $(14,733) | $(11,203) | $(28,845) | $(23,314) |
| Operating Expenses | $16,798 | $13,356 | $33,195 | $29,657 |
| Research & Development | $10,029 | $9,151 | $19,310 | $17,929 |
| General & Administrative | $6,769 | $4,205 | $13,885 | $11,728 |
| Other Income (Net) | $2,065 | $2,153 | $4,350 | $6,343 |
| Cash & Cash Equivalents (End of Period) | $21,576 | $48,277 | $21,576 | $39,448 |
| Accumulated Deficit | $(325,979) | $(267,658) | $(325,979) | $(267,658) |
Liquidity: Net cash used in operating activities for the six months ended June 30, 2025, was $27.1 million. The company holds $21.6 million in cash and cash equivalents as of June 30, 2025.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $3.4 million (26%) for the quarter and $3.5 million (12%) year-to-date compared to the prior year periods. This was driven primarily by higher personnel-related expenses in G&A and increased external services in R&D.
- Equity Conversion: In March 2025, the company converted 21,157 shares of Series A redeemable convertible preferred stock into 21,157,000 shares of common stock. Consequently, there is no preferred stock outstanding as of June 30, 2025.
- Sublease Income: Sublease income from related party GeneFab remained relatively stable at approximately $1.6 million for the quarter, contributing to other income.
- Elimination of Fair Value Gains/Losses: Unlike the prior year, there were no changes in the fair value of the GeneFab Option, Economic Share, or Note Receivable in the current period, as these were previously remeasured to zero or waived.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date. Cash on hand ($21.6 million) is deemed insufficient to fund operations for the next 12 months without additional financing.
- Clinical Updates:
- SENTI-202: Received Orphan Drug Designation from the FDA in June 2025 for relapsed/refractory hematologic malignancies. Preliminary Phase 1 data was announced in April 2025.
- SN301A: Enrollment in the clinical trial for this solid tumor candidate (partnered with Celest Therapeutics) has been stopped due to observed dose-limiting toxicities.
- Capital Raising: The company entered into a new At-The-Market (ATM) agreement in March 2025 with Leerink Partners to sell up to $17.5 million of common stock. In the first six months of 2025, net proceeds from this facility were zero after costs.
- Related Party Risks: GeneFab, a related party and key manufacturing partner, is approximately $3.5 million in arrears on sublease rent and service payments. The company faces risks regarding GeneFab's ability to fulfill manufacturing obligations and pay outstanding debts.
- Internal Controls: The company previously identified a material weakness in internal controls over financial reporting related to insufficient resources in the finance function. Management believes this has been remediated as of June 30, 2025.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" going concern disclosure and the $21.6 million cash balance.
- GeneFab Solvency: Assess the risk exposure related to GeneFab's $3.5 million in overdue payments and its ability to manufacture SENTI-202 without further disruption.
- SN301A Impact: Determine the strategic implications of the halted SN301A trial and whether the company plans to pursue this asset internally or abandon it.
- Dilution Risk: Review the outstanding warrants (31.7 million shares) and the ATM facility, which could lead to significant dilution in future financing rounds.
- Expense Trajectory: Monitor the trend in G&A expenses, which rose significantly ($2.6 million increase in Q2) due to personnel costs, to ensure alignment with cash preservation strategies.